These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35789515)

  • 1. Significance of serum HBV RNA in non-cirrhotic HBeAg-negative chronic hepatitis B patients who discontinue effective antiviral therapy.
    Papatheodoridi M; Papachristou E; Moschidis Z; Hadziyannis E; Rigopoulou E; Zachou K; Villeret F; Magiorkinis G; Lyberopoulou A; Gatselis N; Vlachogiannakos I; Manolakopoulos S; Dalekos GN; Zoulim F; Paraskevis D; Papatheodoridis GV
    J Viral Hepat; 2022 Nov; 29(11):948-957. PubMed ID: 35789515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HBeAg-positive patients with HBsAg  < 100 IU/mL and negative HBV RNA have lower risk of virological relapse after nucleos(t)ide analogues cessation.
    Xie Y; Li M; Ou X; Zheng S; Gao Y; Xu X; Yang Y; Ma A; Li J; Huang Y; Nan Y; Zheng H; Feng B
    J Gastroenterol; 2021 Sep; 56(9):856-867. PubMed ID: 34292372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined viral quasispecies diversity and hepatitis B core-related antigen predict off-nucleos(t)ide analog durability in HBeAg-negative patients.
    Cheng HR; Yang HC; Lin SR; Yang TY; Lin YY; Su TH; Tseng TC; Liu CJ; Kao JH
    Hepatol Int; 2021 Jun; 15(3):582-592. PubMed ID: 33886088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High end-of-treatment hepatitis B core-related antigen levels predict hepatitis flare after stopping nucleot(s)ide analogue therapy.
    Hume SJ; Wong DK; Yuen MF; Jackson K; Bonanzinga S; Vogrin S; Hall SAL; Burns GS; Desmond PV; Sundararajan V; Ratnam D; Levy MT; Lubel JS; Nicoll AJ; Strasser SI; Sievert W; Ngu MC; Sinclair M; Meredith C; Matthews G; Revill PA; Littlejohn M; Bowden S; Visvanathan K; Holmes JA; Thompson AJ
    Liver Int; 2024 Oct; 44(10):2605-2614. PubMed ID: 39007640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel viral markers and the prediction of off-treatment relapse in chronic hepatitis B patients: A systematic review.
    Jaroenlapnopparat A; Chayanupatkul M; Tangkijvanich P
    J Gastroenterol Hepatol; 2021 Sep; 36(9):2349-2362. PubMed ID: 33811375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining Hepatitis B Virus RNA and Hepatitis B Core-Related Antigen: Guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen-Positive Patients With Chronic Hepatitis B.
    Fan R; Peng J; Xie Q; Tan D; Xu M; Niu J; Wang H; Ren H; Chen X; Wang M; Sheng J; Tang H; Bai X; Wu Y; Zhou B; Sun J; Hou J;
    J Infect Dis; 2020 Jul; 222(4):611-618. PubMed ID: 32211776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. End-of-treatment HBsAg, HBcrAg and HBV RNA predict the risk of off-treatment ALT flares in chronic hepatitis B patients.
    Brakenhoff SM; de Knegt RJ; van Campenhout MJH; van der Eijk AA; Brouwer WP; van Bömmel F; Boonstra A; Hansen BE; Berg T; Janssen HLA; de Man RA; Sonneveld MJ
    J Microbiol Immunol Infect; 2023 Feb; 56(1):31-39. PubMed ID: 35941076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of hepatitis B virus core-related antigen in predicting hepatitis B virus relapse after cessation of entecavir in hepatitis B e antigen-negative patients.
    Huang PY; Wang JH; Hung CH; Lu SN; Hu TH; Chen CH
    J Viral Hepat; 2021 Aug; 28(8):1141-1149. PubMed ID: 33932245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pregenomic HBV RNA and Hepatitis B Core-Related Antigen Predict Outcomes in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients Suppressed on Nucleos(T)ide Analogue Therapy.
    Carey I; Gersch J; Wang B; Moigboi C; Kuhns M; Cloherty G; Dusheiko G; Agarwal K
    Hepatology; 2020 Jul; 72(1):42-57. PubMed ID: 31701544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of hepatitis B surface antigen loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in noncirrhotic HBeAg-negative chronic hepatitis B.
    Papatheodoridi M; Hadziyannis E; Berby F; Zachou K; Testoni B; Rigopoulou E; Gatselis NK; Lyberopoulou A; Vlachogiannakos I; Manolakopoulos S; Dalekos GN; Zoulim F; Papatheodoridis GV
    J Viral Hepat; 2020 Feb; 27(2):118-126. PubMed ID: 31562748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum HBV RNA Dynamic and Drug Withdrawal Predictor Value in Patients With Chronic HBV Infection on Long-term Nucleos(t)ide Analogue (NA) Therapy.
    Liu Y; Xue J; Liao W; Yan H; Liang X
    J Clin Gastroenterol; 2020 Sep; 54(8):e73-e82. PubMed ID: 32604147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining end-of-treatment HBsAg and baseline hepatitis B core-related antigen reduce HBV relapse rate after tenofovir cessation.
    Kuo YH; Wang JH; Hung CH; Lu SN; Hu TH; Chen CH
    Hepatol Int; 2021 Apr; 15(2):301-309. PubMed ID: 33665773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term clinical outcome of HBeAg-negative chronic hepatitis B patients who discontinued nucleos(t)ide analogues.
    Manolakopoulos S; Kranidioti H; Kourikou A; Deutsch MM; Triantos C; Tsolias C; Manesis EK; Mathou N; Alexopoulou A; Hadziyannis E; Papatheodoridis G
    Liver Int; 2021 Jan; 41(1):48-57. PubMed ID: 33373114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients.
    García-López M; Lens S; Pallett LJ; Testoni B; Rodríguez-Tajes S; Mariño Z; Bartres C; García-Pras E; Leonel T; Perpiñán E; Lozano JJ; Rodríguez-Frías F; Koutsoudakis G; Zoulim F; Maini MK; Forns X; Pérez-Del-Pulgar S
    J Hepatol; 2021 May; 74(5):1064-1074. PubMed ID: 33278456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetics and Value of Hepatitis B Core-Related Antigen in Patients with Chronic Hepatitis B Virus Infection during Antiviral Treatment.
    Sandmann L; Bremer B; Ohlendorf V; Jaroszewicz J; Wedemeyer H; Cornberg M; Maasoumy B
    Viruses; 2024 Feb; 16(2):. PubMed ID: 38400031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging Diagnostic Tools to Decide When to Discontinue Nucleos(t)ide Analogues in Chronic Hepatitis B.
    Papatheodoridi M; Papatheodoridis G
    Cells; 2020 Feb; 9(2):. PubMed ID: 32093411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum HBV RNA correlated with intrahepatic cccDNA more strongly than other HBV markers during peg-interferon treatment.
    Wang X; Chi X; Wu R; Xu H; Gao X; Yu L; Liu L; Zhang M; Tan Y; Niu J; Jin Q
    Virol J; 2021 Jan; 18(1):4. PubMed ID: 33407619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined baseline HBcrAg and end-of-treatment HBsAg predict HBV relapse after entecavir or tenofovir cessation.
    Tseng TN; Jeng WJ; Hu TH; Wang JH; Hung CH; Lu SN; Chen CH
    J Antimicrob Chemother; 2023 Feb; 78(2):436-439. PubMed ID: 36478233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels.
    Sonneveld MJ; Chiu SM; Park JY; Brakenhoff SM; Kaewdech A; Seto WK; Tanaka Y; Carey I; Papatheodoridi M; van Bömmel F; Berg T; Zoulim F; Ahn SH; Dalekos GN; Erler NS; Höner Zu Siederdissen C; Wedemeyer H; Cornberg M; Yuen MF; Agarwal K; Boonstra A; Buti M; Piratvisuth T; Papatheodoridis G; Chen CH; Maasoumy B;
    J Hepatol; 2022 May; 76(5):1042-1050. PubMed ID: 35092743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hepatitis B.
    Mak LY; Wong D; Kuchta A; Hilfiker M; Hamilton A; Chow N; Mao X; Seto WK; Yuen MF
    Clin Mol Hepatol; 2023 Jan; 29(1):146-162. PubMed ID: 35989092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.